Sex differences in HDL ApoC-III in American Indian youth

Springer Science and Business Media LLC - Tập 3 - Trang 1-7 - 2012
Piers R Blackett1, Sohail Khan2, Wenyu Wang3, Petar Alaupovic4, Elisa T Lee3
1Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, USA
2Cherokee Nation Capitol, Tahlequah, USA
3Center for American Indian Health Research, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, USA
4Oklahoma Medical Research Foundation, Oklahoma City, USA

Tóm tắt

Since American Indians are predisposed to type 2 diabetes (DM2) and associated cardiovascular risk, Cherokee boys and girls (n = 917) were studied to determine whether BMI Z (body mass index Z score) is associated with the apoC-III (apolipoprotein C-III) content of HDL (high density lipoprotein), a previously reported predictor of DM2. An ad hoc cross-sectional analysis was conducted on a previously studied cohort. Participants were grouped by gender-specific age groups (5 to 9, 10 to 14 and 15 to 19 years). ApoA-I (apolipoprotein A-I) and HDL apoC-III were assayed by electroimmunoassay. ApoC-III was measured in whole plasma, and in HDL to determine the molar proportion to apoA-I. General linear models were used to assess association. The HDL apoC-III to apoA-I molar ratio increased by BMI Z quartile in girls aged 10–14 years (p < 0.05 for linear trend, p < 0.05 for difference in BMI Z quartile IV vs. I to III) and aged 15–19 years (p < 0.05 for trend). In boys the increase by BMI Z occurred only at ages 15–19 years (p < 0.01 for trend and for quartile difference). ApoC-III showed an obesity-related increase relative to apoA-I during adolescence beginning in girls aged 10 to 14 years and in boys aged 15 to 19 years. The earlier changes in girls may alter HDL’s protective properties on the β-cell and contribute to their increased risk for DM2.

Tài liệu tham khảo

Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990,263(21):2893–2898. 10.1001/jama.1990.03440210043030 Stern MP: Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996,124(1 Pt 2):110–116. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P: Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996,128(5 Pt 1):608–615. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, et al.: Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000,136(5):664–672. 10.1067/mpd.2000.105141 von Eckardstein A, Schulte H, Assmann G: Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab 2000,85(9):3101–3108. 10.1210/jc.85.9.3101 Onat A, Hergenc G, Ayhan E, Ugur M, Kaya H, Tuncer M, Can G: Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med 2009,26(10):981–988. 10.1111/j.1464-5491.2009.02814.x Kelly LA, Lane CJ, Weigensberg MJ, Toledo-Corral CM, Goran MI: Pubertal changes of insulin sensitivity, acute insulin response, and beta-cell function in overweight Latino youth. J Pediatr 2011,158(3):442–446. 10.1016/j.jpeds.2010.08.046 Expert Committee: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003,26(Suppl 1):S5-S20. Curry MD, Alaupovic P, Suenram CA: Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays. Clin Chem 1976,22(3):315–322. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P: Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 1980,617(3):503–513. 10.1016/0005-2760(80)90016-8 Sobey WJ, Beer SF, Carrington CA, Clark PM, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, et al.: Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins. Biochem J 1989,260(2):535–541. Hoffman RP, Vicini P, Sivitz WI, Cobelli C: Pubertal adolescent male–female differences in insulin sensitivity and glucose effectiveness determined by the one compartment minimal model. Pediatr Res 2000,48(3):384–388. 10.1203/00006450-200009000-00022 Morrison JA, Barton BA, Biro FM, Sprecher DL: Sex hormones and the changes in adolescent male lipids: longitudinal studies in a biracial cohort. J Pediatr 2003,142(6):637–642. 10.1067/mpd.2003.246 Morrison JA, Sprecher DL, Biro FM, Apperson-Hansen C, Dipaola LM: Serum testosterone associates with lower high-density lipoprotein cholesterol in black and white males, 10 to 15 years of age, through lowered apolipoprotein AI and AII concentrations. Metabolism 2002,51(4):432–437. 10.1053/meta.2002.31321 Blackett PR, Blevins KS, Stoddart M, Wang W, Quintana E, Alaupovic P, Lee ET: Body mass index and high-density lipoproteins in Cherokee Indian children and adolescents. Pediatr Res 2005,58(3):472–477. 10.1203/01.pdr.0000176947.98014.44 Brunzell JD, Ayyobi AF: Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003,115(Suppl 8A):24S-28S. Goff DC Jr, D’Agostino RB Jr, Haffner SM, Otvos JD: Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the insulin resistance atherosclerosis study. Metabolism 2005,54(2):264–270. 10.1016/j.metabol.2004.09.002 Freedman DS, Bowman BA, Srinivasan SR, Berenson GS, Otvos JD: Distribution and correlates of high-density lipoprotein subclasses among children and adolescents. Metabolism 2001,50(3):370–376. 10.1053/meta.2001.21027 Posadas Romero C: Some physiopathologic features of metabolic syndrome. Arch Cardiol Mex 2007,77(Suppl 4):S4–42–47. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY, et al.: Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009,150(10):4521–4530. 10.1210/en.2009-0252 Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Brunham LR, Verchere CB, Hayden MR: Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010,53(6):1110–1119. 10.1007/s00125-010-1691-2 Hao M, Bogan JS: Cholesterol regulates glucose-stimulated insulin secretion through phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2009,284(43):29489–29498. 10.1074/jbc.M109.038034 Blackett PR, Blevins KS, Quintana E, Stoddart M, Wang W, Alaupovic P, Lee ET: ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth. Metabolism 2005,54(2):180–187. 10.1016/j.metabol.2004.08.010 Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH: Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004,114(10):1493–1503. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997,17(4):715–722. 10.1161/01.ATV.17.4.715 Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH: Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994,90(1):42–49. 10.1161/01.CIR.90.1.42 Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D’Agostino RB, Vasan RS, Robins SJ: Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006,113(1):20–29. Cromwell WC, Otvos JD: Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004,6(5):381–387. 10.1007/s11883-004-0050-5 Fagot-Campagna A, Knowler WC, Narayan KM, Hanson RL, Saaddine J, Howard BV: HDL cholesterol subfractions and risk of developing type 2 diabetes among Pima Indians. Diabetes Care 1999,22(2):271–274. 10.2337/diacare.22.2.271 Colditz GA, Willett WC, Rotnitzky A, Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995,122(7):481–486. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994,17(9):961–969. 10.2337/diacare.17.9.961 Samuel VT, Petersen KF, Shulman GI: Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010,375(9733):2267–2277. 10.1016/S0140-6736(10)60408-4 Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003,52(10):2461–2474. 10.2337/diabetes.52.10.2461